nirsevimab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Evaluate PK Profile
Conditions
Evaluate PK Profile
Trial Timeline
Jun 22, 2021 → Nov 18, 2021
NCT ID
NCT04840849About nirsevimab
nirsevimab is a phase 1 stage product being developed by AstraZeneca for Evaluate PK Profile. The current trial status is completed. This product is registered under clinical trial identifier NCT04840849. Target conditions include Evaluate PK Profile.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06042049 | Phase 3 | Active |
| NCT05437510 | Phase 3 | Completed |
| NCT04840849 | Phase 1 | Completed |
| NCT04484935 | Phase 2 | Completed |
Competing Products
3 competing products in Evaluate PK Profile
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide/Exenatide extended release + Dapagliflozin + Placebo | AstraZeneca | Pre-clinical | 23 |
| Denosumab | Amgen | Phase 3 | 76 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 1 | 25 |